anti-HER2 CAR-T cell therapy

Anti-HER2 CAR-T cell therapy is a type of adoptive cell immunotherapy that involves genetically engineering a patient's T cells to express a chimeric antigen receptor (CAR) specifically designed to recognize and bind to the Human epidermal growth factor receptor 2 (HER2) protein. HER2 is frequently overexpressed in various malignant solid tumors, making it a target for cancer therapy. Upon administration, these engineered CAR-T cells are intended to target and kill HER2-positive cancer cells, exhibiting potent cytotoxic activity and anti-tumor effects. This therapy is being investigated for its potential to treat a range of HER2-positive cancers, including advanced malignant solid tumors, glioblastoma, pancreatic cancer, breast cancer, and sarcoma, and to overcome resistance to conventional HER2-targeted treatments like trastuzumab. Various approaches are being explored to enhance the efficacy and safety of anti-HER2 CAR-T cells, such as incorporating co-stimulatory domains (e.g., 4-1BB, CD28, Dectin-1) or engineering them to express cytokines (e.g., IL7, CCL19) to improve T-cell expansion, persistence, and infiltration into solid tumors.

Other names

HER2-CAR-T cellsHER-2-CAR-T cellsHER 2-CAR-T cellsHER2-specific CAR-T cellsHER-2-specific CAR-T cellsHER 2-specific CAR-T cells